Why big drugmakers want to buy cancer biotech Seagen

An unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the attention of the world's largest drugmakers on the hunt for the next big opportunity in one of the industry's most lucrative markets.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...